T1D: Artificial pancreas keeps glucose in range for longer
Trial comparing a closed loop device with a sensor-augmented pump shows benefits of new algorithm
24th October 2019
Patients with type 1 diabetes who use an experimental closed-loop artificial pancreas device have blood sugar levels within a target range for longer than those who use a sensor-augmented insulin pump, a study shows.
In the randomised controlled trial of 168 patients with type 1 diabetes aged 14-71, the primary outcome was time spent in a target glucose range of 3.9-10mmol/L.
While the 56 patients in the control group had glucose levels within the target range 59% of the time, the 112 volunteers using Tandem Diabetes Care's Control-IQ
